Company: LICN
Filing Date: 2025-01-29
Form Type: 424B5
Source: 0001213900-25-007741
Chunk: 76

Company: Lichen International Ltd
Filing Date: 2025-01-29
Form: 424B5
Chunk 76
---
 material
adverse change in our operations, limit our ability to offer or continue to offer securities to investors, or cause such securities to
significantly decline in value or become worthless. As the Circular and Trial Measures were newly published, there exists uncertainty
with respect to the filing requirements and their implementation. Any failure or perceived failure of us to fully comply with such new
regulatory requirements could significantly limit or completely hinder our ability to offer or continue to offer securities to investors,
cause significant disruption to our business operations, and severely damage our reputation, which could materially and adversely affect
our financial condition and results of operations and could cause the value of our securities to significantly decline or be worthless.
See “Risk Factors — Risks Related to Doing Business in China — The filing, approval or other administration
requirements of the Chinese Securities Regulatory Commission (the “CSRC”) or other PRC government authorities may be required
in connection with our future offshore offering under PRC law, and, if required, we cannot predict whether or for how long we will be
able to complete the filing procedure with the CSRC and obtain such approval or complete such filing, as applicable” on page 14.

As of the date of this prospectus, according to our PRC counsel,Tianyuan Law Firm, although we are required to complete the filing procedure in connection with our offerings under the Trial Measures, no relevant PRC laws or regulations in effect require that we obtain permission from any PRC authorities to issue securities to foreign investors, and we have not received any inquiry, notice, warning, sanction, or any regulatory objection to this offering from the CSRC, the CAC, or any other PRC authorities that have jurisdiction over our operations.

The Standing Committee of the National People’s
Congress, or the SCNPC, or other PRC regulatory authorities may in the future promulgate laws, regulations or implementing rules that
requires our company or any of our subsidiaries to obtain regulatory approval from Chinese authorities before listing in the U.S. In
other words, although the Company has not received any denial to list on the U.S. exchange, our operations could be adversely affected,
directly or indirectly; our ability to offer, or continue to offer, securities to investors would be potentially hindered and the value
of our securities might significantly decline or be worthless, by existing or future laws and regulations relating to its business or
industry or by intervene or interruption by PRC governmental authorities, if we or our subsidiaries (i) do not receive or